PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Drospirenone - Contraception

PAD Profile : Drospirenone - Contraception

Keywords :
POP, progestogen-only contraceptives, oral contraceptives, contraceptive pills
Brand Names Include :
Slynd

Traffic Light Status

Status 1 of 1.

Status :
Green (see narrative)
Important
Formulations :
  • Tablets
Important Information :
2nd line after desogestrel. Caution - may have different drug interactions to other progestogen-only pills.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
R
SA
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
05 February 2025
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) agreed a Green traffic light status (with restrictions) for drospirenone (Slynd®) for contraception

Restricted use as a second line treatment option, after desogestrel, in women requiring progestogen-only contraception who do not have risk factors for potassium elevation (renal impairment, hypoadrenalism, concomitant use of potassium-elevating medicines)
 

Caution: May have different drug interactions to other progestogen only pills (POP)

Associated BNF Codes

07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.03.02. Progestogen-only contraceptives
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More